Company Overview

Update
Founded:
2001
Headquarters:
Miami Springs, FL
Funding:
$12.80M

Tissuetech offers regenerative amniotic tissue-based products for ophthalmology, optometry, musculoskeletal and wound care markets.

Description

Update

Founded in 2001 by Amy Tseng, President and CEO, and Dr. Scheffer Tseng, Chairman and Chief Scientific Officer, TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since inception, 150,000 human implants have been conducted using the Company’s patented CryoTek™ process and 300 peer-reviewed scientific publications have been produced supporting the technology

platform. The Company has pioneered the clinical application of human amniotic membrane and its role in stem cell research. The Company’s first product, AmnioGraft™, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.

Current Team (3)

Update

Funding Rounds (3) - $12.80M

Update

Investors (2)

Update

Offices/Locations (1)

Update
  • Office

    8305 NW 27th Street

    27th Street

    Miami Springs, FL 33122

    USA